AI data asset · anonymous listing
#2568
- Potential data value
- Assessment available after diligence
- Licensing readiness
- RESTRICTED
- Preferred structure
- Non-exclusive, annual license with usage reporting
Seller identity is never disclosed at this stage. Introduction requires buyer qualification, seller approval and executed confidentiality.
- Industry
- Pharmaceuticals & Life Sciences
- Region
- United States
- Company size
- 500–2,000 employees
- Years operating
- 9+
- Historical data
- 6 years
- Estimated records
- 310,000+ records
- ERP
- SAP
- CRM
- Veeva CRM
- Approx. employees
- 890
- Case Management
- Quality Records
- Financial Records
- Deviation intake and investigation
- CAPA approval chain
- Submission dossier assembly
- Site monitoring visits
Cross-system connectivity
Veeva Vault → SAP → Snowflake
Volume
310,000+ records in scope.
79
weight 12
Historical depth
6 continuous years of operating history.
95
weight 12
Workflow complexity
Multi-step decisions with real exception handling.
90
weight 12
Cross-system connectivity
Records join across 4 systems on shared keys.
74
weight 11
Uniqueness
Pharmaceuticals & Life Sciences operational reasoning is scarce in open corpora.
94
weight 10
Data quality
Structured fields are strong; free-text completeness varies by year.
91
weight 9
Outcome labels
Outcomes are recoverable from downstream records.
81
weight 9
Industry value
Active buyer demand for pharmaceuticals & life sciences agents.
82
weight 8
AI-agent relevance
Tool-using, multi-system workflows suit agent training and evaluation.
74
weight 8
Licensing readiness
Sponsor and CRO agreements restrict transfer.
30
weight 5
Privacy / de-identification complexity
Investigator and subject references in monitoring records.
36
weight 4
Why this asset scored 80
This pharmaceuticals & life sciences asset covers 6 years of deviation intake and investigation and related decisions across Veeva Vault, SAP, Snowflake. Scarcity is the strongest factor: this class of operational reasoning is largely absent from public corpora. The score is held back by licensing constraints that point to a restricted-environment evaluation rather than a data transfer.
- •Vertical AI agents
- •Evaluation benchmarks
- •Document reasoning
Ownership
Company-generated operational records in owned tenants.
Source systems
Veeva Vault, SAP, Snowflake, Microsoft 365.
Third-party data
CRO-generated monitoring reports.
Customer / client data
Investigator and subject references in monitoring records.
Employee data
Approver identities appear in workflow audit trails.
Potential PII
Names and work contact details appear in free text.
Contract restrictions
Sponsor and CRO agreements restrict transfer.
Licensing permissions
Pending rights review.
Retention period
6 years retained; no scheduled destruction.
Geographic restrictions
United States operations only.
Intended AI use
Seller prefers training plus evaluation, no resale.
De-identification requirements
Entity and person pseudonymisation required pre-sample.
Status indicators reflect seller-reported information and SentryRights screening only. No asset is represented as legally licensable until rights and privacy diligence is completed with the seller and, where applicable, its counsel.
Demo data — illustrative sample listings, not live marketplace records
- Volume
- MODERATE
- Historical depth
- HIGH
- Workflow complexity
- HIGH
- Cross-system connectivity
- MODERATE
- Industry uniqueness
- HIGH
- Data quality
- HIGH
- Outcome labels
- HIGH
- PII risk
- MODERATE
- De-identification difficulty
- HIGH
- Licensing readiness
- RESTRICTED
- 1
Buyer submits request
Identity, funding stage and entity are verified before the request moves.
- 2
Buyer provides intended use
Specific model, application and downstream distribution limits stated in writing.
- 3
Platform reviews buyer
SentryRights qualifies the buyer and screens the intended use against seller preferences.
- 4
Seller receives request
Seller sees the buyer profile and intended use while remaining anonymous.
- 5
Seller approves or declines
No identity is disclosed without an explicit seller approval.
- 6
NDA / confidentiality
Mutual confidentiality executed through the platform.
- 7
Identity revealed
Counterparties are introduced only at this point.
- 8
Data diligence begins
Rights review, privacy review and de-identification are coordinated by SentryRights.